Evidence map›Paper›PMID 24316081›Full record

ArticleCell reports2013

Testing the iron hypothesis in a mouse model of atherosclerosis.

Léon Kautz, Victoria Gabayan, Xuping Wang, Judy Wu, James Onwuzurike, Grace Jung, Bo Qiao, Aldons J Lusis, Tomas Ganz, Elizabeta Nemeth

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Iron Dysregulation and Vascular Diseases: A Contemporary Review.Journal of the American Heart Association · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Ironing out macrophages in atherosclerosis.Acta biochimica et biophysica Sinica · 2023
    Review
  7. Article
  8. The role of iron metabolism in chronic diseases related to obesity.Molecular medicine (Cambridge, Mass.) · 2022
    Review
  9. Review
  10. Article
  11. Review
  12. Iron in Cardiovascular Disease: Challenges and Potentials.Frontiers in cardiovascular medicine · 2021
    Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Hepcidin Deficiency Protects Against Atherosclerosis.Arteriosclerosis, thrombosis, and vascular biology · 2019
    Article
  18. Balance of cardiac and systemic hepcidin and its role in heart physiology and pathology.Laboratory investigation; a journal of technical methods and pathology · 2018
    Review
  19. Targeting iron metabolism in drug discovery and delivery.Nature reviews. Drug discovery · 2017
    Review
  20. Safety of intravenous iron in hemodialysis patients.Hemodialysis international. International Symposium on Home Hemodialysis · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Léon KautzDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Victoria GabayanDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Xuping WangDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Judy WuDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
James OnwuzurikeDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Grace JungDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Bo QiaoDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Aldons J LusisDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Tomas GanzDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Pathology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Elizabeta NemethDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: enemeth@mednet.ucla.edu.
University of California, Los Angeles · US

Funding

ULTRASTRUCTURE OF THE INTIMA IN EARLY LESION FORMATIONP01HL030568 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FOGELMAN, ALAN M · 1985 to 2019
$55.2M
Systems genomics of metabolic syndrome traitsP01HL028481 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LUSIS, ALDONS JAKE · 1985 to 2019
$50.2M
The role of iron in atherosclerosis: application of new iron biologyR21HL106374 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEMETH, ELIZABETA · 2011 to 2012
$424k
NHLBI NIH HHS HL106374NHLBI NIH HHS HL28481NHLBI NIH HHS HL30568NHLBI NIH HHS P01 HL028481NHLBI NIH HHS P01 HL030568NHLBI NIH HHS R21 HL106374
6 · The paper itself

Abstract

Hepcidin, the iron-regulatory hormone and acute phase reactant, is proposed to contribute to the pathogenesis of atherosclerosis by promoting iron accumulation in plaque macrophages, leading to increased oxidative stress and inflammation in the plaque (the "iron hypothesis"). Hepcidin and iron may thus represent modifiable risk factors in atherosclerosis. We measured hepcidin expression in Apoe(-/-) mice with varying diets and ages. To assess the role of macrophage iron in atherosclerosis, we generated Apoe(-/-) mice with macrophage-specific iron accumulation by introducing the ferroportin ffe mutation. Macrophage iron loading was also enhanced by intravenous iron injection. Contrary to the iron hypothesis, we found that hepatic hepcidin expression was not increased at any stage of the atherosclerosis progression in Apoe(-/-) or Apoe/ffe mice and that the atherosclerotic plaque size was not increased in mice with elevated macrophage iron. Our results strongly argue against any significant role of macrophage iron in atherosclerosis progression in mice.

Indexed as

AnimalsApolipoproteins EAtherosclerosisCation Transport ProteinsDiet, High-FatDisease Models, AnimalFerroportinHepcidinsIronIron, DietaryMacrophagesMiceMice, Inbred C57BLMutationPlaque, AtheroscleroticApolipoproteins ECation Transport ProteinsFerroportinHepcidinsIronIron, Dietary

Identifiers

PMID24316081
PMCPMC3880128
OpenAlexW2083838269

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.